Ertapenem (MK-0826), a new carbapenem: Comparative in vitro activity against clinically significant anaerobes

Diagnostic Microbiology and Infectious Disease

Volumn 44, Issue 2, 2002, Pages 181-186

  Aldridge, Kenneth E ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM; ERTAPENEM; IMIPENEM; MEROPENEM; METRONIDAZOLE; PIPERACILLIN; TAZOBACTAM; TROVAFLOXACIN;

ARTICLE; BACTERIUM ISOLATE; BACTEROIDES FRAGILIS; DILUTION; DRUG ACTIVITY; DRUG RESISTANCE; FUSOBACTERIUM; IN VITRO STUDY; MICROBIAL SENSITIVITY TEST; NONHUMAN; PEPTOSTREPTOCOCCUS; PORPHYROMONAS; PREVOTELLA; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; BACTERIA, ANAEROBIC; BETA-LACTAMS; DRUG RESISTANCE, MICROBIAL; HUMANS; LACTAMS; MICROBIAL SENSITIVITY TESTS; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 0036890897     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(02)00430-3     Document Type: Article

References (21)

1. Aldridge K.E., Ashcraft D., Cambre K., Pierson C.L., Jenkins S.G., Rosenblatt J.E. Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas and Peptostreptococcus species. Antimicrobial Agents Chemotherapy. 45:2001;1238-1243.
2. Aldridge K.E., Gelfand M., Reller L.B., Ayers L.W., Pierson C.L., Schoenknect F., Tilton R.C., Wilkins J., Henderberg A., Schiro D.D., Johnson M., Janney A., Sanders C.V. A five-year multicenter study of the susceptibility of the Bacteroides fragilis group isolates to cephalosporins, cephamycins, penicillins, clindamycin, and metronidazole in the United States. Diagnostic Microbiology and Infectious Diseases. 18:1994;235-241.
3. Aldridge K.E., Wexler H.M., Sanders C.V., Finegold S.M. Comparison of in vitro antibiograms of Bacteroides fragilis group isolates differences in resistance rates in two institutions because of differences in susceptibility testing methodology . Antimicrobial Agents and Chemotherapy. 34:1990;179-181.
4. Betriu C., Sánchez A., Palau M., Góme M., Picazo J.J. In vitro activities of MK-0826 and 16 other antimicrobials against Bacteroides fragilis group strains. Antimicrobial Agents and Chemotherapy. 45:2001;2372-2374.
5. Fuchs P.C., Barry A.L., Brown S.D. In vitro antimicrobial activity of a carbapenem, MK 0826 (L-749, 345) and provisional interpretive criteria for disc tests. Journal of Antimicrobial Chemotherapy. 43:1999;703-706.
6. Fuchs P.C., Barry A.L., Brown S.D. In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American Medical Centers. Antimicrobial Agents and Chemotherapy. 45:2001;1915-1918.
7. Gill C.J., Jackson J.J., Gerckens L.S., Pelak B.A., Thompson R.K., Sundelof J.G., Kropp H., Rosen H. In vivo activity and pharmacokinetic evaluation of a novel long-acting carbapenem antibiotic, MK-826 (L-749, 345). Antimicrobial Agents and Chemotherapy. 42:1998;1996-2001.
8. Goldstein E.J.C., Citron D.M., Merriam C.V., Warren Y., Tyrrell K.L. Comparative in vitro activities of ertapenem (MK-0826) against 1, 001 anaerobes isolated from human intra-abdominal infections. Antimicrobial Agents and Chemotherapy. 44:2000;2389-2394.
9. Goldstein E.J.C., Citron D.M., Goldman R.J. National hospital survey of anaerobic culture and susceptibility testing methods results and recommendations for improvement . Journal of Clinical Microbiology. 30:1992;1529-1534.
10. Holdeman L.V., Cato E.P., Moore W.E.C. Anaerobe laboratory manual. 4th ed. 1977;Virginia Polytechnic Institute and State University, Blacksburg, Va.
11. Kohler J., Dorso K.L., Young K., Hammond G.G., Rosen H., Kropp H., Silver L.L. In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749, 345) against broad-spectrum β-lactamase- and extended-spectrum β-lactamase producing Klebsiella pneumoniae and Escherichia coli clinical isolates. Antimicrobial Agents and Chemotherapy. 43:1999;1170-1176.
12. Approved standard M11-A4. Methods for antimicrobial susceptibility testing of anaerobic bacteria. 1997;National Committee for Clinical Laboratory Standards, Wayne, PA.
13. Nguyen M.H., Yu V.L., Morris A.J., McDermott L., Wagner M.W., Harrell L., Snydman D.R. Antimicrobial resistance and clinical outcome of Bacteroides bacteremia findings of a multicenter prospective observational trial . Clinical Infectious Diseases. 30:2000;870-876.
14. Nord C.E., Lindqvist L., Olsson-Liljequist B., Tuner K. Beta-lactamases in anaerobic bacteria. Scandinavian Journal of Infectious Diseases. 46:(Suppl):1985;57-63.
15. Oteo J., Aracil B., Alós J.I., Gómez-Garcés J.L. High prevalence of resistance to clindamycin in Bacteroides fragilis group isolates. Journal of Antimicrob Chemotherapy. 45:2000;691-693.
16. Redondo M.C., Arbo M.D.J., Grindlinger J., Snydman D.R. Attributable mortality of bacteremia associated with the Bacteroides fragilis group. Clinical Infectious Diseases. 20:1995;1492-1496.
17. Rotimi V.O., Khoursheed M., Brazier J.S., Jamal W.Y., Khodakhast F.B. Bacteroides species highly resistant to metronidazole an emerging clinical problem? Clinical Microbiology and Infection. 5:1999;166-169.
18. Sandoe J.A.T., Struthers J.K., Brazier J.S. Subdural empyema caused by Prevotella loescheii with reduced susceptibility to metronidazole. Journal of Antimicrobial Chemotherapy. 47:2001;366-367.
19. Summanen P., Baron E.J., Citron D., Strong C., Wexler H.M., Finegold S.M. Wadsworth anaerobic bacteriology manual. 5th ed. 1993;Star Publishing Company, Belmont, Calif.
20. Tally F.P., Snydman D.R., Gorbach S.L., Malamy M.H. Plasmid-mediated transferable resistance to clindamycin and erythromycin in Bacteroides fragilis. Journal of Infectious Diseases. 139:1979;83-88.
21. Wexler H.M., Molitoris D., Finegold S.M. In vitro activities of MK-826 (L-749, 345) against 363 strains of anaerobic bacteria. Antimicrobial Agents Chemotherapy. 44:2000;2222-2224.